4. Meta‐regression of effects of SFA reduction on cardiovascular events.
Regression factor | No. of studies | Constant | Coefficient (95% CI) | P value | Proportion of between study variation explained |
Change in SFA as %E | 8 | 0.01 | 0.05 (‐0.03 to 0.13) | 0.16 | 89% |
Change in SFA as % of control | 8 | 0.26 | 0.01 (‐0.01 to 0.03) | 0.14 | 89% |
Baseline SFA as %E | 8 | 0.68 | ‐0.06 (‐0.15 to 0.04) | 0.19 | 81% |
Change in TC, mmol/L | 12 | 0.03 | 0.69 (0.05 to 1.33) | 0.04 | 99% |
Change in PUFA as %E | 5 | ‐0.01 | ‐0.02 (‐0.08 to 0.03) | 0.25 | 100% |
Change in MUFA as %E | 5 | ‐0.26 | ‐0.03 (‐0.14 to 0.09) | 0.50 | ‐87% |
Change in CHO as %E | 7 | ‐0.11 | ‐0.00 (‐0.05 to 0.05) | 0.92 | ‐273% |
Change in total fat intake as %E | 9 | ‐0.17 | ‐0.01 (‐0.03 to 0.01) | 0.28 | 100% |
Gender* | 13 | ‐0.17 | ‐0.14 (‐0.63 to 0.35) | 0.55 | ‐13% |
Study duration | 13 | ‐0.47 | 0.00 (‐0.01 to 0.02) | 0.76 | ‐24.8% |
CVD risk at baseline** | 13 | ‐0.44 | 0.03 (‐0.48 to 0.55) | 0.89 | ‐39% |
*Gender was coded as follows: 0 = women, 1 = mixed, 2 = men **CVD risk at baseline was coded as follows: 1 = Low CVD risk, 2 = Moderate CVD risk, 3 = existing CVD CHO: carbohydrate CI: confidence interval CVD: cardiovascular disease E: energy MUFA: monounsaturated fatty acid PUFA: polyunsaturated fatty fat SFA: saturated fatty acid TC: total cholesterol